论文部分内容阅读
目的探讨13C-美沙西定呼气试验评估肝硬化患者肝储备功能的临床价值。方法随机选取健康志愿者30例为对照组,肝硬化患者82例为试验组,服用13C-美沙西定75mg后,通过呼气质谱仪检测10个时间段呼出的13CO2含量,得出DOB曲线、MV曲线及CUM曲线,MVmax30、CUM30及CUM120值,并与常规肝功能生化指标及Child-Pugh分级行相关性分析。结果MVmax30、CUM30及CUM120值在对照组及肝硬化ChildA、B、C各组间,除ChildA、B组的CUM120值外,均有显著性差异(P<0·05),MVmax30、CUM30及CUM120值与部分肝功能生化指标及Child-Pugh分级计分有相关性。结论13C-美沙西定呼气试验是1种定量评估肝硬化患者肝储备功能的有效方法。
Objective To investigate the clinical value of 13C-methacetin breath test in assessing liver reserve function in patients with liver cirrhosis. Methods Thirty healthy volunteers were randomly selected as control group and 82 patients with cirrhosis as experimental group. After taking 13C-methacetin 75 mg, the content of 13CO2 exhaled in 10 time periods was detected by exhalation mass spectrometer, and the DOB curve was obtained. MV curve and CUM curve, MVmax30, CUM30 and CUM120 values, and correlation with conventional liver function and Child-Pugh grading. Results The values of MVmax30, CUM30 and CUM120 were significantly different (P <0.05), MVmax30, CUM30 and CUM120 between the control group and ChildA, B and C cirrhosis except CUM120 in ChildA and B groups Value and some biochemical indicators of liver function and Child-Pugh score correlation. Conclusion The 13C-methacetin breath test is an effective method for the quantitative assessment of liver reserve in patients with cirrhosis.